Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
Article Date
July 8, 2025
This article is featured on another website.
Go to article
September 16, 2025
Mytrelle Announces Nature Medicine Publication of Interim Results
Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
September 16, 2025
Mytrelle Announces Nature Medicine Publication of Interim Results
Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
July 16, 2025
Evox Therapeutics Expands Scientific Advisory Board
Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases
July 16, 2025
Evox Therapeutics Expands Scientific Advisory Board
Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases